STAT+: Overton won’t get a vote before midterms
Health department nominees await Senate votes, and we map out what the elections mean for healthy policy.
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 722 articles · page 7 of 21 · fetched about 1 hour ago
STAT+: Anthropic joins ARPA-H clinical AI moonshot, will hold closed-door health care event
In this edition of STAT Health Tech: Oura delays IPO plans, Anthropic joins an clinical AI effort by ARPA-H, and MAHA's…
Read at source →
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s…
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
Novo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui…
Read at source →
Researchers slow neurodegeneration in mice by barring T cells from the brain
A new study in mice led by Washington University in St. Louis researchers suggests that stopping certain immune cells…
Read at source →
STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit…
Read at source →
Why MAHA wants to make health data much more accessible
At a MAHA Institute event, Kennedy and others argued that health data should be more accessible to researchers can…
Read at source →
She’s spent two decades talking to parents who don’t vaccinate their children. Here’s what she’s learned
Jennifer Reich has spent two decades speaking to families about their immunization decisions. In an interview, she…
Read at source →
STAT+: The last ‘breakthrough’ devices to get special treatment from Medicare
New medical devices deemed "breakthrough" by the FDA are no longer automatically eligible for extra Medicare payments.
Read at source →
STAT+: Drug pricing, Medicaid, and research funding: The key policy issues at stake in the midterms
Big shifts in health care policy could emerge depending on who wins the midterms, affecting hospitals and pharma…
Read at source →
Opinion: Child health is the national security crisis we keep ignoring
“National security begins in childhood,” write Tina L. Cheng, Stanley McChrystal, and James M. Perrin.
Read at source →
Opinion: Massive SNAP cuts could mean more children are separated from their families
"We should not make families poorer and then punish them for their poverty," write Sandy Santana and Kristen Weber of…
Read at source →
Risk from toxic metals can persist months after wildfires, Maui study finds
Post-wildfire air quality needs to be monitored long term, suggests a study finding Maui residents had high levels of…
Read at source →
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
Merck discontinued Recarbio, an important antibiotic in the U.S., despite concerns over resistance to superbugs.
Read at source →
Trump administration asks Supreme Court to allow transgender medical care restrictions in prison
The Trump administration asked the Supreme Court on Monday to let it enforce, for now, restrictions on gender-affirming…
Read at source →
STAT+: It really is bleak out there, and list prices matter
Health insurance premiums are skyrocketing, private equity hospital chain goes nonprofit, and more from STAT's Health…
Read at source →
STAT+: AbbVie wins FDA nod for Parkinson’s pill
The FDA has approved AbbVie’s once-daily Parkinson’s pill for sales, based on a late-stage study that showed the drug…
Read at source →STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to…
Read at source →
Trump uses ‘contested’ power to cut more funding to HHS
Late Friday night, the Trump administration clawed back nearly $1 billion in spending approved by Congress, targeting…
Read at source →
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
Blockbuster GLP-1 drugs have transformed the lives of millions of people. Lately, they’re undergoing a makeover of…
Read at source →
Opinion: AI is eroding the barriers that kept biological weapons rare
“Defenses against AI-created bioweapons will take years to build. We don’t have years to spare,” writes Ashish Jha.
Read at source →
Opinion: I discovered a new structure in the heart — just by looking closely
Our finding was remarkable because it had remained hidden within one of the best-studied organs in medical history.
Read at source →
Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?
“We’ve come a long way since the fall of 2001, but we find ourselves with recent widening gaps in public health…
Read at source →
Trump administration uses rare authority to claw back nearly $1B in spending approved by Congress
President Trump is canceling nearly $1 billion in spending approved by Congress, and most of the cuts are focused on…
Read at source →
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
With an eye toward pandemic preparedness, a U.N.-backed agency has signed sub-licensing deals related to generic…
Read at source →
STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an…
Read at source →Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of…
Read at source →STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and…
Read at source →
Federal judge rolls back landmark disability protections
The Justice Department said in June that it would no longer enforce laws that prioritized people with disabilities…
Read at source →
How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
Virtually all of the 175,000 public comments on a 2022 FDA proposal to ban menthol cigarettes were form letters, most…
Read at source →
At least five candidates vie to become the next WHO leader, as questions over U.S. role loom
At least five candidates are in the running to become the next director-general of the WHO, a job that will come with…
Read at source →
STAT+: The head of Kennedy’s new autism project has roots in Iraq War, Sesame Street
Advanced Research Projects Agency for Health is planning a total-lifespan research project on autism: A Q&A with its…
Read at source →
Opinion: RFK Jr.’s use of the National Center for Health Statistics will add confusion to measles deaths count
“A discrepancy between how federal and state public health officials determine measles deaths will only increase public…
Read at source →
Opinion: The ‘died with’ vs. ‘died of’ measles discussion misses something very important
“Arguing over whether someone died ‘with’ or ‘of’ a disease gets us stuck on the last thing that happened.” write two…
Read at source →
STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
Senators focused on asking Overton about vaccines, abortion, and vapes.
Read at source →
The FDA’s Overton era, and dispatches from Shanghai
The Readout LOUD is going international this week with a dispatch from Shanghai, along with notes on the FDA's Overton…
Read at source →